Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
This study has been completed.
Study NCT00056433   Information provided by National Institutes of Health Clinical Center (CC)
First Received: March 12, 2003   Last Updated: September 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sickle Cell Anemia
Additional conditions recognized in this trial
Anemia
Anemia, Sickle Cell
More general conditions related to this trial
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Interventions listed in this trial
Hydroxyurea
L-Arginine
Sildenafil
Additional drug interventions recognized in this trial
Nitric Oxide
More general drug interventions related to this trial
Anti-Asthmatic Agents
Antineoplastic Agents
Antioxidants
Antisickling Agents
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Endothelium-Dependent Relaxing Factors
Enzyme Inhibitors
Free Radical Scavengers
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nucleic Acid Synthesis Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
National Institutes of Health Clinical Center (CC)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services